Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
To demonstrate the pharmacodynamic (PD) equivalence of enoxaparin Rovi (100 mg/mL) 100-mg SC
injection to Clexane® (100 mg/mL) 100-mg SC injection in healthy volunteers.
As secondary objective, to evaluate the safety and tolerability of enoxaparin Rovi (100
mg/mL) in healthy volunteers.